United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets.
| Revenue (Most Recent Fiscal Year) | $2.88B |
| Net Income (Most Recent Fiscal Year) | $1.20B |
| PE Ratio (Current Year Earnings Estimate) | 11.89 |
| PE Ratio (Trailing 12 Months) | 12.78 |
| PEG Ratio (Long Term Growth Estimate) | 6.13 |
| Price to Sales Ratio (Trailing 12 Months) | 4.83 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.12 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 11.28 |
| Pre-Tax Margin (Trailing 12 Months) | 52.23% |
| Net Margin (Trailing 12 Months) | 40.44% |
| Return on Equity (Trailing 12 Months) | 19.33% |
| Return on Assets (Trailing 12 Months) | 16.73% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.46 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.23 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 2.17 |
| Book Value per Share (Most Recent Fiscal Quarter) | $150.91 |
| Earnings per Share (Most Recent Fiscal Quarter) | $6.63 |
| Earnings per Share (Most Recent Fiscal Year) | $24.64 |
| Diluted Earnings per Share (Trailing 12 Months) | $25.06 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 45.11M |
| Free Float | 40.46M |
| Market Capitalization | $14.45B |
| Average Volume (Last 20 Days) | 0.43M |
| Beta (Past 60 Months) | 0.58 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 94.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |